Cubist Systematic Strategies, LLC Incyte Corp Transaction History

Cubist Systematic Strategies, LLC

$15.8 Billion
Q3 2024

A detailed history of Cubist Systematic Strategies, LLC transactions in Incyte Corp stock. As of the latest transaction made, Cubist Systematic Strategies, LLC holds 71,015 shares of INCY stock, worth $5.01 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

71,015

Holding current value

$5.01 Million

% of portfolio

0.03%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$57.33 - $68.61 $4.07 Million - $4.87 Million	71,015 New	71,015 $4.69 Million
Q1 2024 May 15, 2024	BUY	$56.55 - $66.59 $7.48 Million - $8.81 Million	132,345 Added 46.13%	419,241 $23.9 Million
Q4 2023 Feb 14, 2024	SELL	$52.16 - $64.19 $19.7 Million - $24.2 Million	-377,290 Reduced 56.8%	286,896 $18 Million
Q3 2023 Nov 14, 2023	BUY	$57.77 - $65.93 $11.8 Million - $13.5 Million	204,390 Added 44.45%	664,186 $38.4 Million
Q2 2023 Aug 14, 2023	BUY	$60.95 - $75.51 $20.6 Million - $25.5 Million	337,689 Added 276.55%	459,796 $28.6 Million
Q1 2023 May 15, 2023	BUY	$70.23 - $86.01 $5.45 Million - $6.68 Million	77,668 Added 174.77%	122,107 $8.82 Million
Q4 2022 Feb 14, 2023	SELL	$67.18 - $84.11 $7.54 Million - $9.44 Million	-112,182 Reduced 71.63%	44,439 $3.57 Million
Q3 2022 Nov 14, 2022	BUY	$66.18 - $82.86 $3.4 Million - $4.26 Million	51,398 Added 48.85%	156,621 $10.4 Million
Q2 2022 Aug 15, 2022	BUY	$66.18 - $83.18 $2.38 Million - $3 Million	36,034 Added 52.08%	105,223 $7.99 Million
Q1 2022 May 16, 2022	SELL	$66.02 - $79.71 $12.4 Million - $15 Million	-187,775 Reduced 73.07%	69,189 $5.5 Million
Q4 2021 Feb 14, 2022	BUY	$63.34 - $74.11 $11.1 Million - $13 Million	175,351 Added 214.86%	256,964 $18.9 Million
Q3 2021 Nov 15, 2021	SELL	$68.67 - $84.02 $1.97 Million - $2.41 Million	-28,701 Reduced 26.02%	81,613 $5.61 Million
Q2 2021 Aug 16, 2021	BUY	$79.87 - $87.53 $1.13 Million - $1.24 Million	14,118 Added 14.68%	110,314 $9.28 Million
Q1 2021 May 17, 2021	SELL	$76.02 - $100.5 $2.01 Million - $2.66 Million	-26,449 Reduced 21.57%	96,196 $7.82 Million
Q4 2020 Feb 16, 2021	BUY	$80.74 - $97.7 $53,288 - $64,482	660 Added 0.54%	122,645 $10.7 Million
Q3 2020 Nov 16, 2020	BUY	$85.07 - $109.69 $4.22 Million - $5.45 Million	49,641 Added 68.62%	121,985 $10.9 Million
Q2 2020 Aug 14, 2020	BUY	$74.18 - $108.93 $4.55 Million - $6.68 Million	61,278 Added 553.75%	72,344 $7.52 Million
Q1 2020 May 15, 2020	SELL	$63.18 - $85.97 $8.91 Million - $12.1 Million	-141,002 Reduced 92.72%	11,066 $810,000
Q4 2019 Feb 14, 2020	BUY	$73.04 - $95.72 $8.01 Million - $10.5 Million	109,721 Added 259.1%	152,068 $13.3 Million
Q3 2019 Nov 14, 2019	BUY	$72.82 - $86.52 $2.21 Million - $2.62 Million	30,284 Added 251.05%	42,347 $3.14 Million
Q2 2019 Aug 14, 2019	SELL	$73.52 - $88.7 $1.03 Million - $1.24 Million	-14,002 Reduced 53.72%	12,063 $1.03 Million
Q1 2019 May 15, 2019	BUY	$63.56 - $88.17 $1.62 Million - $2.25 Million	25,547 Added 4931.85%	26,065 $2.24 Million
Q4 2018 Feb 14, 2019	SELL	$58.5 - $69.94 $480,051 - $573,927	-8,206 Reduced 94.06%	518 $33,000
Q3 2018 Nov 14, 2018	SELL	$61.75 - $74.23 $481,650 - $578,994	-7,800 Reduced 47.2%	8,724 $603,000
Q2 2018 Aug 14, 2018	BUY	$60.85 - $83.98 $797,500 - $1.1 Million	13,106 Added 383.44%	16,524 $1.11 Million
Q1 2018 May 15, 2018	SELL	$83.06 - $100.98 $1.18 Million - $1.43 Million	-14,175 Reduced 80.57%	3,418 $285,000
Q4 2017 Feb 14, 2018	BUY	$93.56 - $116.6 $1.29 Million - $1.6 Million	13,755 Added 358.39%	17,593 $1.67 Million
Q3 2017 Nov 14, 2017	BUY	$109.15 - $138.27 $418,917 - $530,680	3,838	3,838 $448,000

Others Institutions Holding INCY

# of Institutions

645

Shares Held

186M

Call Options Held

714K

Put Options Held

557K

View Full List

About INCYTE CORP

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $15.7B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

More about INCY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.

Account

Cubist Systematic Strategies, LLC Incyte Corp Transaction History